Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Market Cap	2.03T
Revenue (ttm)	7.88B
Net Income (ttm)	-23.09B
Shares Out	30.36M
EPS (ttm)	-770.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,705
Average Volume	141,713
Open	67,700
Previous Close	67,000
Day's Range	67,300 - 71,100
52-Week Range	25,450 - 74,300
Beta	0.74
RSI	57.56
Earnings Date	Nov 11, 2025

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 18
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.